{"id":4213,"date":"2026-11-05T09:00:00","date_gmt":"2026-11-05T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4213"},"modified":"2026-11-11T20:45:24","modified_gmt":"2026-11-12T00:45:24","slug":"registry-links-kit-inhibition-to-lower-aml-transformation-in-sm-ahn","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4213","title":{"rendered":"Registry Links KIT Inhibition to Lower AML Transformation in SM-AHN"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"512\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261111_Blood_SM_AHN_KIT_TKI_Therapeutic_Indications-768x512.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4238\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261111_Blood_SM_AHN_KIT_TKI_Therapeutic_Indications-768x512.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261111_Blood_SM_AHN_KIT_TKI_Therapeutic_Indications-300x200.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261111_Blood_SM_AHN_KIT_TKI_Therapeutic_Indications-1024x683.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261111_Blood_SM_AHN_KIT_TKI_Therapeutic_Indications.png 1536w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>International registry investigators (academic)<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>Peer-reviewed publication (Blood)<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>KIT D816V-selective tyrosine kinase inhibitors (class exposure)<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>Not applicable (registry analysis)<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>KIT D816V<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>Systemic mastocytosis with associated hematologic neoplasm<\/p>\n<h4>Summary<\/h4>\n<p>Source-gap recovery: a peer-reviewed Blood research article appeared online November 5, 2026. In an international registry of 201 patients with systemic mastocytosis with an associated hematologic neoplasm (SM-AHN), exposure to a KIT D816V-selective tyrosine kinase inhibitor was associated with less AML transformation and longer overall survival. Association is not proof of prevention.<\/p>\n<p>The authors reported median overall survival of 37.9 months in the exposed group versus 17.8 months in the comparison group (P&lt;.001), and 36-month cumulative AML transformation incidence of 5.9% versus 27.1% (P&lt;.001). The article is online ahead of print. This is a November 5 publication missed in the immediate 36-hour window and recovered within the required 14-day source-gap reconciliation.<\/p>\n<h4>Deep Analysis<\/h4>\n<p>SM-AHN combines mast-cell disease with a separate myeloid neoplasm, making AML transformation biologically and clinically consequential. <strong>Interpretation A:<\/strong> KIT D816V inhibition could suppress a mast-cell or shared-clone contribution to leukemic progression. Supporting evidence is the large observed transformation separation and survival association. Contradicting evidence is the nonrandomized design: treatment selection, baseline myeloid subtype, disease severity, competing therapies and immortal-time effects could explain part of the difference.<\/p>\n<p><strong>Interpretation B:<\/strong> selective TKIs are a marker of access to contemporary specialist care or more favorable biology rather than a direct modifier of AML evolution. Supporting evidence is the registry design and potentially heterogeneous co-treatment. Against it, the magnitude and endpoint concordance warrant prospective testing. Competing-risk analysis, adjusted time-dependent exposure modeling, molecular lineage tracking, and randomized or carefully emulated comparisons would upgrade the causal thesis. An attenuated association after these checks would downgrade it. Drug-specific exposures, toxicity and durable response by AHN subtype remain necessary for treatment selection.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>Systemic mastocytosis is usually driven by activating KIT D816V, which sustains mast-cell proliferation. SM-AHN also contains a separate hematologic neoplasm, often myeloid. KIT D816V-selective TKIs inhibit mutant KIT kinase signaling; this study assessed class exposure rather than validating one product for AML prevention.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li>Verified: 201-patient international registry; 37.9 versus 17.8 month survival; 5.9% versus 27.1% 36-month AML transformation.<\/li>\n<li>Independent corroboration: peer-reviewed journal indexing and PubMed metadata.<\/li>\n<li>Missing: randomization, fully assessable confounder control and agent-specific benefit in the retrieved abstract.<\/li>\n<li>Falsifier: no reduction in prospective AML transformation after comparable baseline risk and exposure time are controlled.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>An important disease-modification hypothesis in a rare, high-risk hematologic overlap syndrome. The evidence justifies deeper review of the full cohort methods and prospective trial design, while the present result remains observational.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 4 of 5. Signal Direction: uncertain. Confidence in Facts: high for the reported registry estimates and online date; moderate for their generalizability. Confidence in Interpretation: low to moderate because causal attribution is unresolved.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Source-gap recovery: a peer-reviewed Blood research article appeared online November 5, 2026. In an international registry of 201 patients with systemic mastocytosis with an associated hematologic neoplasm (SM-AHN), exposure to a KIT D816V-selective tyrosine&#8230;<\/p>\n","protected":false},"author":1,"featured_media":4238,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[76,1438,1437],"class_list":["post-4213","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-acute-myeloid-leukemia","tag-kit-d816v","tag-systemic-mastocytosis"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4213","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4213"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4213\/revisions"}],"predecessor-version":[{"id":4246,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4213\/revisions\/4246"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4238"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4213"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4213"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4213"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}